• 1
    Treglia G, Cason E, Stefanelli A et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: A meta-analysis. Clin. Auton. Res. 2012; 22: 4355.
  • 2
    King AE, Mintz J, Royall DR. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov. Disord. 2011; 26: 12181224.
  • 3
    Treglia G, Cason E, Gabellini A, Giordano A, Fagioli G. Recent developments in innervations imaging using iodine-123-metaiodobenezylguadine scintigraphy in Lewy body disease. Neurol. Sci. 2010; 31: 414422.
  • 4
    Veltman CE, Boogers MJ, Meinardi JE et al. Reproducibility of planar (123) I-metaiodobenzylguanidine myocardial scintigraphy in patients with heart failure. Eur. J. Nucl. Med. Mol. Imaging 2012; 39: 15991608.
  • 5
    Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl. Med. Commun. 1992; 13: 513521.
  • 6
    Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential syndrome. Clin. Auton. Res. 2001; 11: 351355.
  • 7
    Estorch M, Carrio I, Mena E et al. Challenging the neuronal MIBG uptake by pharmacological intervention: Effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. Eur. J. Nucl. Med. Mol. Imaging 2004; 31: 15751580.
  • 8
    McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB Consortium. Neurology 2005; 65: 18631872.
  • 9
    Iritani S, Tsuchiya K, Arai T, Akiyama H, Ikeda K. An atypical autopsy case of Lewy body disease with clinically diagnosed major depression: A clinical radiological and pathological study. Neuropathology 2008; 28: 652659.
  • 10
    Donald S. The role of dopamine and norepinephrine in depression. Prim. Psychiatry 2007; 14: 2123.
  • 11
    Muraoka T, Oku E, Sugataka K, Yamada S. A case of severe Parkinsonism associated with short-term treatment with milnacipran. Clin. Neuropharmacol. 2008; 31: 299300.
  • 12
    Kosaka Y. Evaluation of norepinephrine kinetics at the cardiac sympathetic nerve terminals in failing human hearts: Assessment by 123I-metaiodobenzylguanidine scintigraphy with imipramine. Akita J. Med. 2006; 33: 7789.
  • 13
    Svestka J. Antidepressives of the 3rd, 4th and 5th generation. Cesk. Psychiatr. 1994; 90: 319.
  • 14
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, 1994.
  • 15
    Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 10201025.
  • 16
    Yoshita M, Taki J, Yokoyama K et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006; 66: 18501854.
  • 17
    Hanyu H, Shimizu S, Hirao K et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement. Geriatr. Cogn. Disord. 2006; 22: 379384.
  • 18
    Cohen J. A power primer. Psychol. Bull. 1992; 112: 155159.
  • 19
    Folstein M, Folstein S, McHugh P. ‘Mini-mental State’: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975; 12: 189198.
  • 20
    McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies. Neurology 2005; 65 (2 of 2): 18631872.
  • 21
    Puozzo C. Pharmacokinetic study of F2207 by single dosing in the elderly subject. Pierre Fabre, 1988.
  • 22
    Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int. Clin. Psychopharmacol. 1996; 11 (Suppl. 4): 1527.